Invention Grant
- Patent Title: Anti-ICOS and anti-PD-1 antibody combination therapy
-
Application No.: US16322538Application Date: 2017-08-03
-
Publication No.: US11649289B2Publication Date: 2023-05-16
- Inventor: Sabyasachi Bhattacharya , Paul M. Bojczuk , Heather L. Jackson , Mili Mandal , Hong Shi , Sapna Yadavilli , Niranjan Yanamandra
- Applicant: GlaxoSmithKline Intellectual Property Development Limited
- Applicant Address: GB Middlesex
- Assignee: GlaxoSmithKline Intellectual Property Development Limited
- Current Assignee: GlaxoSmithKline Intellectual Property Development Limited
- Current Assignee Address: GB Middlesex
- Agent Carly A. Shanahan; Nicole Ginanni
- International Application: PCT/IB2017/054764 2017.08.03
- International Announcement: WO2018/025221A 2018.02.08
- Date entered country: 2019-02-01
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/395 ; A61P35/00 ; A61K39/00

Abstract:
The present invention provides methods for increasing expression of ICOS on an effector T cell comprising contacting said effector T cell with an anti-PD-1 antibody. The present invention also provides methods for decreasing expression of ICOS on a regulatory T cell comprising contacting said regulatory T cell with an anti-PD-1 antibody. The present invention provides methods for increasing sensitivity to an agent directed to ICOS in a human comprising administering to the human an anti-PD1 antibody. The present invention also provides methods of treating cancer in a human in need thereof comprising administering an anti-PD-1 antibody and an anti-ICOS antibody to said human, wherein the anti-PD-1 antibody increases T cell sensitivity to the ICOS antibody.
Public/Granted literature
- US20190256599A1 ANTI-ICOS AND ANTI-PD-1 ANTIBODY COMBINATION THERAPY Public/Granted day:2019-08-22
Information query